Aspergillosis is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Aspergillosis have a 87.5% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Aspergillosis compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aspergillosis overview
Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss, and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma, and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungals, and surgery.
For a complete picture of PTSR and LoA scores for drugs in Aspergillosis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.